Status:

UNKNOWN

An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis

Lead Sponsor:

Eric Simpson

Collaborating Sponsors:

Regeneron Pharmaceuticals

Conditions:

Atopic Dermatitis

AD

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

24-week, open-label, single-arm longitudinal study of patients with AD, including a comparison between baseline values for adult patients with moderate-to-severe AD and untreated normal control patien...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • All patients:
  • Male or female, 18 years or older
  • Willing and able to comply with clinic visits and study-related procedures
  • Provide signed informed consent
  • Have applied a stable dose of topical emollient (moisturizer) once daily for at least 7 days before the day 1 visit
  • AD patients only:
  • Chronic AD
  • Eczema Area and Severity Index (EASI) ≥16 at screening and day 1 visits
  • Investigator's global assessment (IGA) ≥3 (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe) at the screening and day 1 visits
  • Body surface area of involvement of AD (BSA) ≥10% at screening and day 1 visits
  • Documented recent history (within 6 months before screening visit) of inadequate response to treatment with topical medications or for whom topical treatments are otherwise medically inadvisable
  • Exclusion Criteria for all patients (not all inclusive):
  • Prior use of dupilumab or other anti-IL-4 treatments (prescription or as part of a clinical study) within 1 year of screening
  • Treatment with an investigational drug within 8 weeks or within 5 half-lives (if known) before the day 1 visit, whichever is longer
  • Having used immunosuppressive drugs or phototherapy within the last 4 weeks
  • Treatment with TCS or TCI within 1 week before the day 1 visit
  • Regular use (\>2 visits/week) of a tanning booth/parlor within 4 weeks before the screening visit

Exclusion

    Key Trial Info

    Start Date :

    September 1 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 31 2021

    Estimated Enrollment :

    45 Patients enrolled

    Trial Details

    Trial ID

    NCT04520308

    Start Date

    September 1 2020

    End Date

    March 31 2021

    Last Update

    August 20 2020

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.